Welcome to our first Domainex newsletter featuring all the latest news, blogs and upcoming events.
No images? Click here
Domainex News
All the latest news and industry insights from the Domainex team
Tom Mander, CEO
Welcome to our first Domainex newsletter!
We’d like to share our latest exciting news and developments with you in a quarterly newsletter which we hope you will enjoy reading. Your feedback will be most welcome and of course please let us know if you want to opt out of receiving these.
After what has been a 12 month period like no other, I’m extremely proud of everyone at Domainex rising to the challenges we’ve faced to keep our programme of medicines research on track for our ever-growing portfolio of international clients. To have grown our revenues by over 40% has been nothing short of remarkable in such times.
This quarter we’ve been focused on further adding new members to our scientific ranks and adding to our technical capabilities to drive our clients’ drug discovery projects, for instance the investment we’ve made in the Creoptix WAVEdelta platform. We are planning several exciting new service releases over the coming months ahead.
On a personal note, I’d like to thank all of our clients for their business, to welcome our new team members who’ve joined us and to thank everyone for all their hard work in adapting so well to the continued working practices we follow across 7 operating days/week. I am grateful to the UK Government for its COVID-19 vaccination programme which has so far seen about a quarter of our staff receive their first jabs.
We look forward to welcoming new clients, new recruits and continuing with an ever more innovative set of projects entrusted to us by our clients in Q2.
Tom
Domainex invests in Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform
We’ve expanded our drug discovery offering with the WAVEdelta from Creoptix. This instrument uses Grating-Coupled Interferometry (GCI) to measure target binding on sensor chips, achieving superior resolution compared to traditional Surface Plasmon Resonance (SPR).
Driving scientific advancement with diversity
We celebrated International Day of Women and Girls in Science by recognising the fantastic contributions of some of the women in our team. Read more
Domainex recognised as leading CRO
We were recently awarded ‘Drug Discovery CRO of the Year – Europe’ at the GHP Healthcare & Pharmaceutical Awards and nominated for ‘Best CRO’ at the OBN Awards. Read more
Follow us on social media
Upcoming events
Kinase 2021
14th April 2021
32nd symposium on Medicinal Chemistry in Eastern England
29th April 2021
BioIntegrates
20th May 2021
OBN Awards
11th June 2021
BioForward
17th June 2021
